| 货号 | 18740-1mg |
| 描述 | Cyclin-dependent kinases (Cdks) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.1 Cdk1/5 Inhibitor is a pyrazolo [3,4-b] quioxaline that inhibits Cdk1/cyclin B and Cdk5/p25 (IC50s = 600 and 400 nM, respectively).2 It less potently inhibits GSK3β (IC50 = 1 µM) and does not block Cdc25 activity.2 This compound is used to help define the roles of Cdk1 and Cdk5 in various signaling pathways.3,4,5 |
| 别名 | NSC 693868; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Bettayeb, K.,Baunbaek, D.,Delehouze, C., et al. CDK inhibitors roscovitine and CR8 trigger Mcl-I down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 1(4), 369-380 (2010). 2.Ortega, M.A.,Montoya, M.E.,Zarranz, B., et al. Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorganic & Medicinal Chemistry 10(7), 2177-2184 (2002). 3.Chen, S.,Xu, Y.,Yuan, X., et al. Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proceedings of the National Academy of Sciences of the United States of America 103(43), 15969-15974 (2006). 4.Nguyen, T.K., and Grant, S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Molecular Cancer Therapeutics 13(3), 662-674 (2014). 5.Topanurak, S.,Ferraris, J.D.,Li, J., et al. High NaCl- and urea-induced posttranslational modifications that increase glycerophosphocholine by inhibiting GDPD5 phosphodiesterase. Proceedings of the National Academy of Sciences of the United States of America 110(18), 7482-7487 (2013). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 185.2 |
| 分子式 | C9H7N5 |
| CAS号 | 40254-90-8 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |